Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of LY3039478 plus dexamethasone in relapsed or refractory T-ALL/T-LBL
MOH_2017-03-20_000092Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of crenigacestat in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) (4 arms), sponsored by Eli Lilly and Company. Started Dec 2016; status: completed.
02
Drugs
crenigacestat
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on MOH_2017-03-20_000092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-20_000092.